Achieve Faster Ophthalmic Drug Development
End-to-End Support
Altasciences has over 50 years of experience with all ophthalmic therapeutic indications. Our advanced technological platforms and comprehensive regulatory expertise support your program from lead candidate selection to market.
Our end-to-end expertise includes:
- many different types of formulations, including nanoparticles and ocular implants;
- ocular studies performed in rodent and non-rodent species;
- FIH to Phase lla focused, more than 40 ophthalmology trials completed; and
- state-of-the-art bioanalytical instrumentation and assay platforms.
Explore our full range of integrated ophthalmic drug development services and how we can accelerate your timeline by up to 40%.
Do you have an ocular drug compound in your pipeline? Speak with one of our experts and let’s get you started!
Related resources that may interest you:
- Webpage: Comprehensive Ophthalmic Drug Development Solutions
- Scientific Journal: The Complexities of Early-Phase Ophthalmic Drug Development
- Scientific Poster: Ocular Imaging and Microscopic Analysis of Focal Chorioretinal Defects in Rabbits